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Abstract
Respiratory virus infections are associated with Chronic Obstructive Pulmonary
Disease (COPD) exacerabtions. Human Rhinovirus (HRV) has been found in
many exacerbations and is believed to be a triggering factor, however a causative
relationship has not been proven. For healthy individuals infected with HRV,
symptoms are mainly observed from the upper respiratory tract while COPD pa-
tients experience more symptoms from the lower respiratory tract. High concen-
trations of inflammatory cells and molecules have been found in COPD patients
and HRV is believed to increase these levels even further. A deeper understand-
ing of the immune mechanisms is required in order to understand the underlying
mechanisms of these occurences.
In this master thesis a temporal model of the dynamics between virus and the
immune system during a HRV infection was developed. The model was utilized
to achieve numerical estimates for parameters governing the mechanisms in the
immune system. Through a sensitivity analysis the interplay between different
cells in the model was examined. The reliability of the parameter estimates were
evaluated through an identifiability analysis.
The model was able to capture the dynamics of virus and the majority of the mech-
anisms included from the immune system. The sensitivity analysis proved that the
outcome of the infection was highly sensitive for changes of the parameters gov-
erning the early immune response, production and removal of virus. Lastly the
identifiability analysis showed that the model and available data were sufficient
to achieve reliable parameter estimates.
Combined with another model that takes the spatial effects into account this model
could be used to simulate the infection and immune dynamics in the human lung.
With such a model hypothesis regarding the differences in viral occurrence be-
tween upper and lower respiratory tract could be tested.
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Chapter 1
Introduction
1.1 Background
Chronic obstructive pulmonary disease(COPD) is an expanding epidemic with
global prevalence. With an aging population and increased levels of air pollution
the future spread of the disease is expected to expand even further. COPD is a
chronic disease and patients can live with their symptoms for many years. Al-
though exacerbations, sudden worsening of the symptom states, can occur often
and in their most severe form, lead to death. The exacerbations are associated
with a loss in lung function, impaired quality of life as well as enormous health
care costs [1]. The latest research shows that viral infections cause the majority
of these exacerbations. Therefore, developing drugs with antiviral properties can
potentially decrease morbidity and improve patients quality of life. However, the
exact mechanism by which virus trigger exacerbations is poorly understood and
the movement towards an antiviral drug have been made even more difficult by
clinical results from different studies showing contradictory results.
Infection of respiratory viruses, such as Human Rhinoviruses(HRV) was previ-
ously thought to be relatively benign illnesses, mainly effecting the upper respira-
tory tract. However, experimental data suggest that the infection can spread from
the upper to the lower tract and that HRV could be linked with COPD exacerba-
tions [2]. Although the detection rates vary and viruses are found in stable COPD
patients as well. Therefore a causal relationship between HRV infections and ex-
acerbations in patients with COPD have not yet been made [1].
Patients with COPD have an immune response that is constantly elevated with
levels of inflammatory cells that are higher compared to healthy individuals. Ad-
ditionally, HRV is a pathogen that, even in healthy subjects, trigger the immune
response in such a way that the cold symptoms that appear after an infection is
considered to be a result from the inflammatory response and not from the virus it-
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self [3]. Therefore, by investigating the dynamics of HRV and the immune system
interactions during an infection one can learn about the pathogenesis of exacer-
bations caused by HRV.
1.2 Project
This thesis has been part of a bigger project held in collaboration between CSBD
and AstraZeneca in Gothenburg, Sweden. It has been shown in earlier studies that
HRV function as a trigger for exacerbations in COPD patients but the underlying
dynamics are not yet known. The goal of the bigger project is to deepen the
knowledge about these mechanisms by developing a spatiotemporal model that
can be used to simulate the virus and the immune dynamics. In parallel with the
work presented in this thesis report another master thesis student has worked on
developing a spatial model of the human lung with the aim to simulate the viral
spread without a counteracting immune system. Eventually the immune system
would have to be added to the spatial model but before such extensions can be
made it is advantageous to outline which reactions that are likely to occur and
which cells and molecules that are going to interact with the virus in the specific
scenario of a COPD exacerbation caused by respiratory virus infection.
1.2.1 Aim
The aim of the project has been to develop a model of virus and immune dynamics
during a HRV infection and by investigating the dynamics and interactions learn
about the pathogenesis of exacerbations caused by HRV.
1.2.2 Objective
The thesis project was divided into the following three sections:
1. A model was developed and used to achieve numerical estimates on param-
eters that govern the mechanisms in the model
2. A sensitivity analysis was performed of the model to observe how varia-
tions of different parameters effected the model dynamics
3. An identifiability analysis was performed in order to explore if the model
and available clinical data were sufficient to describe the dynamics and
achieve reliable parameter estimates
2
Chapter 2
Theory
This section presents the theory about the project. Initially the medical conditions
related to COPD are outlined in section 2.1 followed by what is known about
HRV(section 2.2) and the pathogenesis in healthy subjects(2.2.1). As aforemen-
tioned, research has shown contradictory results of the pathogenesis of HRV in
patients with COPD. Some of these results are outlined in section 2.2.2. Finally
some modelling approaches are presented in section 2.3.
2.1 Chronic Obstructive Pulmonary Disease
Chronic Obstructive Pulmonary Disease (COPD) is a degenerative disease effect-
ing the respiratory system. It has been shown to have a causal relationship with
tobacco smoking but pollution and overexposure to other micro particles may
also play a role in the progression of the disease. The disease is characterized by
airflow obstruction, chronic cough and sputum overproduction and many COPD
patients experience a limitation in performing daily life activities due to shortness
of breath or fatigue [4]. Chronic Obstructive Pulmonary Disease is often used as
an umbrella-term for the conditions Chronic Bronchitis and Emphysema and in
some cases these two are even referred to as subtypes of COPD [5].
Chronic Bronchitis (CB) is associated with an increased production of mucus,
also called hypersecretion, as a response to inflammation in the epithelium of
the airway walls. The inflammation is a response to an elevated immune system
triggered by chronic irritation from gases and particles. Normally mucus clear-
ance occurs naturally as the rhythmic movement of the celia, covering the epithe-
lium, shovels the mucus up to the oral cavity. Nevertheless, in COPD patients
the celiary function is often impaired leading to decreased elimination of mucus.
As a result the overproduction of mucus in combination with ciliary dysfunction
leads to chronic cough. [6]
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The other condition of COPD, Emphysema, is an illness that causes shortness
of breath as a result of impaired alveoli, the smallest compartments of the lungs
where the gas exchange takes place. The modern view of Emphysema is that
chronic airway inflammation causes the alveolar destruction and that smoking fur-
ther contributes to the inflammation. When the body is in a state of inflammation
the levels of inflammatory cells are locally elevated. These cells secrete proteases
which are chemicals that can destroy the walls and the elastic fibres of the alveoli,
see figure 2.1 [7]. Some of the inflammatory cells, like the macrophages exist nat-
urally in the alveoli and hence a baseline production of proteases also exists. In a
healthy lung the alveoli themselves produce antiproteases to repress the amount
of protease as an attempt to maintain equilibrium. However, in the emphysema-
tous lung this production in impaired, leading to an overproduction of protease
and an ongoing destruction of tissue. Exposure to toxins from smoking and pol-
lution will further induce the inflammatory response in the sense that it triggers
secretion of other inflammatory chemicals, so-kalled cytokines and chemokines.
Figure 2.1: An example of normal alveoli and alveoli with emphysema. In pa-
tients with emphysema a gradual degradation of the small airways may cause
collapse of the alveolar walls. [8]
The elastic fibers in the walls of the alveoli and bronchioles allow recoiling to
occur during inhalation and exhalation of gases. In the emhysematous lung the
inhalation has to be done with force, due to a decrease in elasticity in the small
airways. The forced inhalation results in a narrowing of the bronchioles which in
combination with the loss of elastic fibers also makes it hard for the patients to
exhale.
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2.2 Human Rhinovirus as a pathogen
The presence of respiratory viruses such as Human Rhinovirus(HRV) is often as-
sociated with COPD exacerbations. However it has also been recognized as a
lower respiratory pathogen in patients with asthma, infants, elderly patients, and
immunocompromised hosts. There are currently no approved therapies for pre-
vention or treatment of HRV and the major support that patients can be given are
symptom relieving products [2]. It is known that the magnitude of the antibody
response during and after an infection depends on the type of pathogen. Some
viruses induce a high production of long lived antibodies while the response to
other viruses might be only a short lived population of antibodies or none at all.
In the case of HRV no such connection has been made. With HRV some patients
expressed antibodies, lasting for approximately 2-4 years, while others did not
have a production at all [9]. Efforts of producing a vaccine has been hindered
by this reason as well as by the large number of serotypes. These serotypes have
shown little or no cross-reactivity between each other meaning that an antibody or
pharmaceutical that works effectively on one serotype might be useless to another
[10].
The pathological effects of HRV in COPD patients have so far been hard to de-
fine, mostly because different studies have presented conflicting results. This is
probably due to factors such as differences in sampling time, in vivo versus in
vitro experiments, differences in time from infection to investigation, effects of
treatment and differences with sampling during naturally occurring and induced
exacerbations [1]. In the following section the pathogenesis of HRV in healthy
subjects will be described followed by what is known to be the differences in the
pathogenesis for patients with COPD.
2.2.1 Pathogenesis of HRV in healthy subjects
An HRV infection normally starts by self-inoculation with the virus by hand into
the nose or into the eyes [11]. Inoculation of HRV in healthy subjects has shown
that the nasopharynx is the most likely area where HRV is initially detected. This
is supposedly because the nasopharynx serves as an endpoint for mucus clear-
ance from the nose, paranasal sinuses and middle ear cavities [2]. The nose also
has a temperature that is optimal for HRV replication. The targets for HRV are
the epithelial cells that constitutes the walls of both the upper and lower respi-
ratory tract and the major receptor in which the virus attaches to the cells is the
membrane bound protein ICAM-1. HRV virus has been shown to upregulate the
expression of ICAM-1 in order to maximize the infection of epithelial cells [12].
After successfully docking to the receptors the viral RNA enters the cell, where it
translates and replicates. New virions are released after 8-10 hours when the in-
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fected epithelial cell lyses [3]. Other respiratory viruses, such as influenza, cause
a destruction of the neighboring epithelial cells as the infection spreads, but HRV
on the other hand has not been associated with such morphological changes of the
host tissue [3][2].
A typical immune response to a viral infection consist of both the innate and
adaptive immune responses. The innate immunity is the bodys unspecific and
initial response that prevents, controls and eliminates the pathogen. The innate
response is connected to and initiates the adaptive immune response which is
the secondary, specific response that is unique for each pathogen. Cells that are
said to be part of the innate response are the dendritic cells, neutrophils, natural
killer cells, monocytes(that mature and become macrophages), mast cells, ba-
sophils and eosinophils. Among these are mast cells, basophils and eosinophils
not associated with HRV infection. There are two types of lymphocytes that are
associated with the adaptive immune system. These are B-lymphocytes (B-cells)
and T-lymphocytes (T-cells). The T-cells can further be divided into CD8+ that
become cytotoxic T-cells (CTLs) and CD4+ that become T helper cells when ac-
tivated. An overview of the cells in the immune system can be seen in figure
2.2.
Figure 2.2: The cells of the innate and adaptive immune system. [13]
The Innate response
Following the infection of epithelial cells and within a few hours after inocula-
tion inflammatory mediators, so-kalled cytokines and chemokines, are released by
cells in the surrounding tissue. These mediators are the cell’s signaling molecules
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and they can either be pro or anti inflammatory. The chemokines are a subgroup
of cytokines, they are chemotactic cytokines, meaning their major function is to
attract other cells by inducing chemotaxis. The first cytokines to be found after
HRV infection are type-I interferons (IFN). IFN are produced by infected cells
and dendritic cells and the levels peak approximately 1 or 2 days after the peak
virus titer [3]. These molecules have gotten their name from their ability of in-
terfering with the viral infection. Type-I interferons inhibit the viral replication
in both infected and uninfected cells by blocking the receptors on the uninfected
cells as well as by interfering with the viral replication in already infected cells
[14].
Apart from the type-I interferons multiple other cytokines are produced by the
infected cells. Some of these are anti inflammatory with the major function of
neutralizing the pro inflammatory cytokines in order to stabilize and calm the
inflammation. Others have a chemotactic effect that attract other inflammatory
cells. As soon as the chemokine levels increase, inflammatory cells like neu-
trophils, natural killer cells and macrophages start to migrate towards the area of
infection. These cells do not exist in the tissue but circulate in the cardiovascular
system until they are recruited from the blood into a site of infection. As the neu-
trophils, natural killer cells and macrophages arrive they attack the infected cells
and in that way they impede with the viral spread.
The Adaptive response
Dendritic cells have a special role in the immunological defence in the sense that
they connect the innate immune system with the adaptive. The dendritic cells
deliver antigens, which could be part of a pathogen or the pathogen itself, to the
lymph nodes and display it to naive CD8+ and CD4+ T-cells. Upon activation
the CD8+ T-cells differentiate into Cytotoxic T Lymphocytes (CTLs) and travel
to the periphery where they destroy infected cells and virus. When the CD4+ T-
cells activate they proliferate into CD4+ helper T-cells with the major function of
assisting B lymphocytes with the production of antibodies [14]. The antibodies
further assist in the elimination of the virus. The antibody response does however
not appear until after 2-5 weeks which implies that the recovery from an infec-
tion with HRV, which usually occurs within 7-10 days, must be a result of other
components of the immune system [3].
2.2.2 Pathogenesis of HRV in patients with COPD
Active smoking but also exposure to cigarette smoke has shown to upregulate the
expression of the epithelial receptor ICAM-1 [15].
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The Innate response
Different results have been given regarding the production of type-I IFN by HRV
infected COPD cells. In [16] epithelial cells from the lower respiratory tract of
COPD patients and controls were infected with HRV in vitro. In this study neither
of the groups showed any production of IFN at baseline but increased levels after
infection. Additionally, results from [1] in which COPD samples from the lower
respiratory tract, cultured ex vivo, of controls and COPD patients indicated on a
deficient IFN production by the COPD cells. The deficient IFN production was
accompanied by a deficient production of the interferon induced cytokine IP-10.
Results also indicate on an increased basal levels of some pro-inflammatory cy-
tokines. In [16] results showed that epithelial cells, infected in vitro, from the
lower respiratory tract of COPD patients expressed more IL-6 and IL-8 than con-
trols. This result was also obtained in [17] where samples were taken from the
lower respiratory tract from COPD patients during exacerbations. From the re-
sults in [17] the authors made the conclusion that patients with more frequent
exacerbations had higher baseline cytokine levels in the lower respiratory tract.
Patients with stable COPD had positive correlations between high sputum IL-6
and IL-8 levels and longer history of smoking. These findings could be important
for the pathogenesis since positive correlations have been found between virus
load and IL-6, IL-8 levels from the lower respiratory tract[1].
In [17] higher levels of IL-8 were also associated with increased cell count of neu-
trophils. Furthermore the neutrophils from the lower respiratory tract increased
significantly over some days in the COPD group but not for controls, as reported
in [1].
The Adaptive response
In [18] samples from the lower respiratory tract were taken from controls and
COPD patients upon infection with HRV. No differences in any of the T-cell sub-
sets (CD4+ and CD8+) could be found between the groups at baseline. Further-
more they showed that circulating T-cells were recruited from the blood to the
lungs in COPD patients during an HRV infection. They also showed that T-cell
numbers in the lower respiratory tract correlated with increased virus load and
that T-cell clearance was not impaired in COPD patients.
2.3 Different modeling approaches
When it comes to modeling biological systems and particularly the immune sys-
tem countless different theories and models have previously been proposed. De-
8
pending on the question that is addressed one model approach might be more
beneficial than others. The goal of using a certain model could be to estimate cer-
tain parameters, to test competing hypotheses or to study the interplay between a
pathogen and a host. Immune responses are part of a complex system that does
not only range over a large temporal scale with reactions occurring within mil-
liseconds to days or weeks but also on a large spatial scale including cell to cell
distances but also mechanisms that involve the whole body. [19]
Depending if the aim is to study temporal, spatial or both effects this might be
important to assess before choosing a modeling method. Furthermore details like
what type of relations that should exist between different objects and how the re-
sults should be presented might also effect the final choice of method. [20]
The factors that are modeled, which could be cells or molecules, are often de-
scribed as different compartments or components. The relation between these
components are governed by equations that may or may not change the status of
one entry or the compartment as a whole. The rates in which these changes occur
are determined by unique parameters. [19]
A model that is depending on time is said to be a dynamic model whereas a
model that does not take time in consideration is a static model. Time could fur-
ther on be treated continuously, as is the case in Ordinary Differential Equations
(ODEs) and Partially Differential Equations (PDEs), or discrete like in Cellular
Automatons (CA). Spatial differences could be modeled continuously, as in PDEs
or discrete as in CA or other Agent-Based Models (ABM). Finally, the states of
the entries can be modeled continuously, as in PDEs, or discrete, in ABMs [20].
The models that allow states on their entries or agents can further be separated
into a group with agents fixed on a grid(such as in CAs) and a group where agents
move freely(such as in ABM).
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Chapter 3
Methods
3.1 Materials
The experimental data that has been used in this thesis comes from the paper
Experimental Rhinovirus Infection as a Human Model of Chronic Obstructive
Pulmonary Disease Exacerbation [1] by Mallia et al. They present results from
an experiment where they infected 13 subjects with COPD and 13 control subjects
with a similar smoking history but with normal lung function. After inoculation
the concentrations in phlegm from nose and lower airways (sputum) of virus,
inflammatory cells and cytokines were measured daily. The data that has been
used in this thesis were concentrations of virus in phlegm from the nose(16 time
points), concentration of the cytokines IL-6(9 time points) and IL-8(9 time points)
in sputum as well as the number of neutrophils(9 time points) in sputum. To each
dataset information about standard deviation was also provided. The data was
also assessed for normal distribution.
3.2 The Model
In the theory section of this thesis some modeling approaches were presented. The
method that was decided upon and utilized further in the thesis have been ordinary
differential equations with delays (DDEs) since they allow for computationally
simple simulations and easily can be extended or reduced. Furthermore DDEs are
functions of time which simplifies the comparison with the clinical data that also
was presented over time. The mathematical details of this modeling technique
will be described in the following section.
3.2.1 Ordinary Differential Equations
An Ordinary Differential Equation (ODE) is an equation of one or more functions
and their derivatives. For ODEs the functions depend only on one independent
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variable and if this variable is time the notation becomes y(t). An ODE of nth
order can be given on the form
y(n)(t) = f (t,y(1)(t), ...,y(n−1)(t)) (3.1)
where y(i) is used to denote the i:th derivative of y with respect to t, that is, yi = d
iy
dt i
for all i=0,1,2...n. An ODE of first order then becomes
y1(t) =
d1y
dt1
= f (t,y(t)) (3.2)
In equation 3.2 the term f is a known function of y and y(t) is called a state
variable. ODEs can be used for modeling dynamical systems such as chemical
reactions in the cell or the dynamics of an influenza outbreak in a population
of a species. The state variables may be called either compartments, species or
compounds depending on the field of application. Equation 3.2 describes the dy-
namics of one such compartment and by integration it gives the time course y(t)
of the concentration or quantity of the variable. [21]
Henceforth an initial condition, y0 and for the model specific parameters, θ , might
be added to the equation, as can be seen below.
dy
dt
= f (t,y(t),θ) y0 = y(t0) (3.3)
So far, the left side of equation 3.3 only describes the dynamics of one particular
variable. In order to include more species the model can be extended to form a
system of m differential equations.
dy1
dt
dy2
dt
...
dym
dt
=

f1(t,y(t),θ)
f2(t,y(t),θ)
...
fm(t,y(t),θ)
 y¯0 =

y1(t0)
y2(t0)
...
ym(t0)
 (3.4)
In equation 3.4 fi i=1...m are known functions and y(t)i = (y1(t), ...,ym(t))T is
a m-dimensional variable vector for all i=1...m. y¯0 is a m-dimensional vector
containing the initial conditions and θ are vectors of unknown parameters. ODEs
can be on either linear or non-linear form. The non-linear equations seldomly
have exact solutions which emply that solutions only can be found by numerical
approximation.
3.2.2 Delayed Differential Equations
The delayed differential equations (DDE) are similar to ordinary differential equa-
tions with the exception that they have delays on the state variables. These delays
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can either be constant or time-dependent. This implies that the derivatives at the
current time step depends on the solutions from the derivatives at previous times.
The delays are often associated with the underlying physiological processes, for
example the production time for a certain protein or the delay caused by protein
transport. The general form of a first order DDE can be seen in equation 3.5. Here
the delays are chosen such that min(τ1,τ2, ...,τp)> 0.
dy
dt
= f (t,y(t),y(t− τ1),y(t− τ2), ...,y(t− τp))) (3.5)
When the delays are introduced in the ODEs this infer that the history of the state
variables at previous times has to be taken in consideration. To give an example,
in the case with ODEs the rate of change at the initial time point was given by
y(t0). The DDEs require information from the whole interval [t0− τ, t0] so the
rate of change at the initial point becomes y(t0− τ). Similarly, in order to have
the rate of change at time points t0+ ε one needs to know y(t0) and y(t0− τ+ ε).
The values of a state variable at previous times are stored in a function called a
history function.
As with the ODEs the DDEs can also be nonlinear. A majority of these nonlinear
equations cannot be solved analytically so instead a numerical approximation has
to be done. Many approximation methods exist but a group of widely used meth-
ods for solving first order ODEs are the Runge-Kutta methods. The DDE solver of
choice in this thesis, dde23, developed for MATLAB, utilizes the Runge-Kutta
methods in order to solve nonlinear DDEs. The mathematics behind the approx-
imation method for the differential equations is a comprehensive area per se and
has not been the focus of this thesis to analyze and therefore the details have been
omitted.
3.2.3 The Model
Equations
The equations that make up the model presented in this section have been chosen
based on the literature review that was done in the beginning of this project as well
as in consideration with Hoda Sharifian and Christopher McCrae at AstraZeneca.
Since the immune system consists of a diversity of different cells and cytokines,
connected through both positive and negative feedback reactions, modeling the
system as a whole would be impossible. Instead the results from the literature
review were used to decide which cells and cytokines to include as variables in
the model. The final choice of cells and cytokines can be seen in table 3.1.
The first three variables are susceptible cells, infected cells and virus. The sus-
ceptible cells serve as the target pool for virions to infect and after the virions
12
Symbol Definition
S Susceptible epithelial cells
I Infected epithelial cells
V Free virions
F Free IFN-β
C Free IL-8
N Neutrophils
L Free IL-6
P Free IP-10
T CD8+ T-cells
DC Dendritic cells in epithelial tissue
Table 3.1: Variable definitions.
successfully infect them they become infected cells. The virus variable, V, repre-
sents the free virus that exists in the mucus layer. This was decided upon since
the clinical data was collected from the phlegm but it is important to mention that
a percentage of virions at an area of infection might also be inside the epithelial
cells or attached to receptors on epithelial cells, dendritic cells, in the blood etc.
Furthermore the cytokines IFN-β were included since they with their ability to put
the infected cells in an anti viral state might have an important role in inhibiting
the viral spread. Elevated concentrations of the chemokine IL-8 and neutrophils
have been found in some patients with COPD and HRV infections, hence they
were added to the model. The chemokines IL-6 and IP-10 function as attractors
for CD8+ T-cells. Their concentrations have also been found elevated in patients
with COPD during HRV infection. CD8+ T-cells are believed to be important for
clearing the infection and they have shown to be present both in COPD patients
and in control groups. Lastly dendritic cells were added to the model since they
throughout the infection are believed to be a major producer of many important
cytokines, as for example IFN-β . The cytokines in this model account only for the
free molecules that exist in mucus but as for virus a percentage of these molecules
might also be attached to cell surfaces, inside cells, in blood etc.
When the variables were decided upon the system of DDEs was constructed.
Equation 3.6 to 3.14 represent evolution of numbers of susceptible cells (S), in-
fected cells (I), free virions (V), IFN-β (F), IL-8 (C), neutrophils (N), IL-6 (L),
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IP-10 (P) and CD8+ T-cells (T) respectively.
dS
dt
= gS−β1V S (3.6)
dI
dt
= β1V S−β2I−β12NI−β18T I−β19FI (3.7)
dV
dt
=
β3
(1+β4F)
I−β7SV −δVV (3.8)
dF
dt
= β5I+β13DCV −β6F (3.9)
dC
dt
= gC +β8I−β9C (3.10)
dN
dt
= gN +β10C[t− τ1]−β11N (3.11)
dL
dt
= gL+β14I[t− τ2]−β9L (3.12)
dP
dt
= β15F [t− τ3]−β9P (3.13)
dT
dt
= β16L+β17P−δT T (3.14)
Susceptible cells S, in the absence of infection, proliferate with a rate gs. They
are infected by free virus at rate β1V and converted to infected cells I. Infected
cells decay at a rate β2. The infected cells can also be killed by neutrophils at rate
β12N, CD8+ T-cells at rate β18T or die through apoptosis induced by IFN-β at a
rate β19F. Free virus is produced by infected cells at a rate β3I but the production
gets inhibited as IFN puts the infected cells in an antiviral state. This is modeled
as a saturation term 1(1+β4F) . The free virus is reduced at rate β7S as they infect
the susceptible cells and decay or is removed due to mucus movement at a rate
δV . IFN-β F is produced by infected cells and dendritic cells, DC, at a rate β5
and β13DC respectively. IFN-β decay with a rate β6. In absence of infection,
IL-8 (C), remain at equilibrium gC with a turn over rate of β9. If virus is present
infected cells produce IL-8 at a rate β8I. Neutrophils remain at equilibrium gN
in absence of infection and turn over at a rate β11. Neutrophils are recruited to
the site of infection at a rate of β10C as a response to elevated IL-8 levels. This
recruitment is delayed with a constant τ1. IL-6 (L) remain at equilibrium gL in
absence of infection and decay with a rate β9. Furthermore IL-6 is produced by
infected cells with a rate of β14I but after a delay of τ2 hours. IP-10 (P) is pro-
duced in response to increased IFN-β levels at a rate of β15F and this production
is delayed with τ3 hours. IP-10 decay with a rate of β9. CD8+ T-cells are recruited
from the periphery at a rate of β16L from IL-6 and β17P from IP-10. They die at
a rate δT .
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For simplicity the number of dendritic cells(DC) are defined as constant. These
cells both exist in the tissue and migrate to the area of infection. While at the site
of infection they mature and some gets activated and continue to the lymph nodes
where they participate in the activation of antigen specific T-cells. Including the
dynamics of the DC population would increase the complexity of the model, pos-
sibly without improving the accuracy of the results. DCs count as an important
producer of IFN so excluding them is not an option. By defining the DCs as con-
stant it is assumed that IFN is produced by those DCs that exist and remain in the
tissue.
Systems of ODEs are often supported by a graphical model to make the equa-
tions easier to interpret for the reader. Such a model can be seen in figure 3.1.
Figure 3.1: Visual representation of the DDE model. Virus infect susceptible
cells. The infection is inhibited by IFN-β . IFN-β is produced by infected cells
and dendritic cells. IFN-β induce the production of IP-10 and may also induce
apoptosis of the infected cells. While in their infected state, the cells produce
IL-6. IL-6 together with IP-10 attracts CD8+ T-cells that kills infected cells. The
infected cells also produce IL-8. IL-8 attracts neutrophils that also kills infected
cells. The model is designed by the author of this thesis with animations from
[14].
Initial Conditions
Initial conditions were added to the model based on the data from Mallia et al.
if available or from other literature. The susceptible cells were initialized to 106
based on results from Mitchel et al. in [22] and the number of initially infected
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cells as well as the initial number of IFN-β were both set to zero according to
[23]. The initial number of virus was set to 10 which is an estimate about the
1-30 virions needed to infect a new host [10]. The initial concentrations of IL-8
and IL-6 and the quantity of neutrophils were taken from the data provided in
Mallia et al. This was done by taking the concentrations measured at time t = 0,
or baseline as they refer to it, and use these values as initial conditions. The initial
concentration of IP-10 was set to zero since only limited data on this cytokine
could be found. The number of CD8+ T-cells were initialized as zero since these
cells do not exist in the tissue naturally but arrive during an infection. Furthermore
the model was initialized with 1000 DCs which is an approximation made from
the assumption of one DC per thousand epithelial cells [10]. The initial conditions
with their respective references can be seen in table 3.2.
Symbol Value Unit Reference
S0 (Susceptible cells) 1000000 cells [22]
I0 (Infected cells) 0 cells [23]
V0 (Virus) 10 copies/ml [10]
F0 (IFN-β ) 0 molecules [23]
C0 (IL-8) 174 pg/ml [1]
N0 (Neutrophils) 103 cells [1]
L0 (IL-6) 20 pg/ml [1]
P0 (IP-10) 0 pg/ml -
T0 (CD8+ T-cells) 0 pg/ml -
DC (Dendritic cells) 1000 cells [10]
Table 3.2: Initial conditions for equation 3.6 to 3.14.
3.2.4 Optimization procedure
In order to obtain values for the unknown parameters, such as production rate
constants and decay rates, the system of equations, (3.6) to (3.14), was fitted to
the virus data from Mallia et al. This was done using the optimization procedure
weighted least squares. The aim of an optimization through fitting is to find the
parameters that yield the best fit of the equations to the data. In order do evaluate
the agreement of predictions and data the goodness of the fit is calculated by an
objective function that can be of different type depending on the optimization
routine. The objective function utilized in this thesis was the weighted sum of
squares(WSS) between the fit and the data.
WSS =∑
i
(
f (xi,θ)− xobs,i
σi
)2
(3.15)
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In equation 3.15 the term f (xi,θ) represents the output from the nonlinear DDEs
with the parameter set θ . xobs,i represents the observed data and i=1...N where N
is the number of samples. The differences between predictions and observations
are weighted with the standard deviations, σi, to each sample. The aim is then
to find the parameters that minimize the objective function and hence finds the
solution to equation 3.16.
min
θ
[
WSS
]
= min
θ ∑i
(
f (xi,θ)− xobs,i
σi
)2
(3.16)
The numerical procedure of the optimization was implemented using the function
lsqcurvefit in Matlab R2017b. The function was used with default settings.
The fitting was proceeded on data from Mallia et al. The data sets of virus col-
lected from the upper respiratory tract as well as IL-6, IL-8 and neutrophils from
the lower respiratory tract was utilized in the fitting procedure.
A total of 25 parameters were fitted in the optimization procedure but since the
available data was limited the parameters had to be divided into smaller sets and
optimization performed on each subset. Hence the optimization carried out was
a local optimization. The parameters were divided into four subsets containing 6,
6, 6 and 7 parameters respectively. This gave 2-3 data points for each parameter
which is about the least possible in order to get a good fit according to the recom-
mendation given in [24].
In order to limit the parameter search space for the lsqcurvefit function
boundaries were added on all parameters that were fitted. For some parameters
reference ranges were found in literature and for others the boundaries had to be
determined by the author. All the parameters that were fitted together with their
units and reference ranges, if available, can be seen in table 3.3.
When a model is nonlinear and fitted to a dataset with few samples the landscape
of possible solutions obtained when searching for a best fit in a multiple parame-
ter space might exhibit many local optima [25]. The search for a global optimum
could be enhanced by increasing the number of steps but often this is not enough.
To ensure that the solution found by the optimization algorithm was indeed the
best fit a multistart approach was implemented together with the lsqcurvefit
algorithm. This means that the fitting was performed multiple times, each from
a new starting position i.e with a new set of starting parameters. The starting pa-
rameters were chosen randomly by the algorithm within the boundaries for each
parameter. A number of 25 multistarts were used.
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Parameter Unit Param. ranges from literature Ref
β1 (copies/ml)−1(day)−1 [6e-06, 1.7e-04] [26]
β2 (day)−1 [2.5e-01, 4.0] [27]
β3 (copies/ml)(day)−1 - -
β4 dim.less [1e-08, 3.4e-03] [23]
β5 (molecules/cell)(day)−1 - -
β6 (day)−1 [1, 80] [27]
β7 (day)−1(cell)−1 - -
β8 (pg/ml)(cell)−1(day)−1 [3.8e-03, 1.5e-01] [28]
β9 (day)−1 [1, 80] [27]
β10 (Neutrophils/day)(pg/ml)−1 - -
β11 (day)−1 [1e-01, 2.4] [28]
β12 (Neutrophil)−1(day)−1 [2.5e-06, 1e-03] [28]
β13 (molecules/cell)(day)−1(pg/ml)−1 - -
β14 (pg/ml)(cell)−1(day)−1 [3.8e-03, 1.5e-01] [28]
β15 (day)−1 [3.8e-03, 1.5e-01] [28]
β16 (cells/day)(ml/pg)−1 - -
β17 (cells/day)(ml/pg)−1 - -
β18 (day)−1(cell)−1 [1e-06, 1e-05] [10]
β19 (molecules)−1(day)−1 - -
δV (day)−1 [3.1, 8.7] [26]
δT (day)−1 [1e-02, 1e-01] [29]
gS (day)−1 - -
gC (pg/ml)(day)−1 - -
gN (cells/day) - -
gL (pg/ml)(day)−1 - -
τ1 (h) peak approx. 9-12 dpi. [1]
τ2 (h) peak approx. 3 dpi. [30]
τ3 (h) peak approx. 2-3 dpi. [23]
Table 3.3: Parameters included in the DDE model. Estimates for parameter β1
to gL were found by fitting the differential equations to virus data or by manually
changing the parameters in order to find a good fit. Estimates for τ1 to τ3 were
found by manually changing their respective values. Reference ranges for some of
the parameters were found in literature and used as boundaries in the optimization
routine. dpi. = days post infection.
3.3 Sensitivity analysis
The sensitivity analysis serves two purposes. The first one is to examine how the
model behaviour changes as a single parameter is varied. Secondly, it allows to
see which of the parameters that has a large impact on model behaviour [23]. In
this thesis the sensitivity analysis was performed according to the One Factor At
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a Time (OFAT) approach. As the name OFAT suggests this analysis is performed
by varying the value of one parameter at a time while holding the others fixed.
From the system of equations (3.6) to (3.14) 25 parameters were included in the
sensitivity analysis. The parameters that were excluded from the analysis were
the time constants, τ1 to τ3, governing the delay of the equations. The OFAT
analysis is computationally efficient and requires only n+1 model runs for a n-
dimensional parameter space which made it a suitable choice for this application
since the model contains relatively many parameters.
3.3.1 Virus sensitivity
In the first part of the sensitivity analysis the changes in viral load was observed
while the parameters were varied. This was done by first fitting the DDE model,
equation (3.6) to (3.14), to data from Mallia et al. in order to obtain estimates for
parameter β1 to gL. These values were used as baseline values for the parameters.
Thereafter each of the parameters were varied one at a time in steps of four be-
tween 0.5, 0.75, 1.5 and 2 of their baseline values. For each step the DDEs were
solved and a new trajectory for the virus concentration was achieved yielding four
new trajectories for each parameter. For each step the l2-norm, equation 3.17,
between the trajectory obtained with the baseline parameter and the trajectory
obtained with the modified parameter was calculated.
l2 = ‖x− xde f ault‖2 =
√
∑
i
(
xi− xde f ault,i
)2 (3.17)
In equation (3.17) xi is the vector obtained with the modified parameter and
xde f ault,i the vector obtained with the baseline parameters.
The output of the l2-norm has the same unit as the data that it is applied on. Hence
the results from the virus sensitivity analysis was given in log10(copies/ml)which
is the unit used for virus in the paper from Mallia et al. In order to make the out-
puts from the l2-norm easier to interpret and compare with each other they were
normalized with the virus peak value from the trajectory obtained with the base-
line parameters as seen in equation (3.18).
l2,normalized =
l2
xpeak
(3.18)
3.3.2 Other variables sensitivity
Since it was of interest in this project to model not only the virus dynamics but
also the other variables in a biologically meaningful way the sensitivity analysis
was extended to investigate how each parameter affected each of the variables in
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the DDE model.
The procedure, which was similar to the one exploring virus sensitivity, started by
fitting the DDE model to the virus data from Mallia et al. to get a set of baseline
parameter values as well as baseline trajectories for each of the variables. From
their baseline values the parameters were varied one at a time in steps of four be-
tween 0.5, 0.75, 1.5 and 2 times their initial values. For each step the DDEs were
solved in order to achieve four new trajectories for each variable. The l2-norm
was then calculated between the baseline trajectory and the trajectories obtained
with the modified parameters. This process was repeated for all the parameters.
The outputs from the l2-norm was normalized by the peak value of their respec-
tive variable. The parameters were then classified into sensitive, partly sensitive
and stable depending on the size of the l2-norm.
3.3.3 Use of the model to test two hypotheses
If a model is able to describe the dynamics it is designed for it can be used to
test different hypotheses that have been postulated about the behaviour of the sys-
tem. In this thesis this was done by trying to replicate two results that have been
obtained during clinical experimentation. This was done by changing some pa-
rameter values, solving the system of DDEs and observing the changes of the
trajectories.
Elevated neutrophil levels
Mallia et al. showed in [1] that the number of neutrophils are higher in COPD
patients than in controls during an infection. Therefore the parameters governing
baseline growth of IL-8 (gC), baseline growth of neutrophils (gN) and the neu-
trophil migration rate (β10) were increased while observing the changes of the
neutrophil trajectory. The initial condition of neutrophils was also changed from
103 cells, which was the baseline value for controls, to 127 cells which was the
baseline value for COPD patients.
Impaired production of IFN-β
The results from Mallia et al. also suggested that a deficient production of IFN-β
may contribute to increased susceptibility to virus infection in COPD subjects.
To test this hypothesis the parameters governing IFN-β production induced by
infected cells (β5) and by dendritic cells (β13) were decreased while changes of
the virus trajectory was observed.
20
3.4 Identifiability analysis
A critical challenge with biological models is that they tend to have a lot of pa-
rameters whose values usually are unknown for the modeler and hence have to
be estimated. It may also be that the available experimental data is only from
one or a few species in the model. If this is the case then the amount and quality
of data might not be sufficient to estimate the model parameters unambiguously
[31]. It could also be that the model itself is not appropriately designed to de-
scribe the dynamics. In any of these scenarios it could be that the parameters are
non-identifiable. It might however still be possible to find an estimate for a non-
identifiable parameter but the achieved value will not be uniquely identified and
may not be reliable. An identifiability analysis was performed on parameter β1 to
gL to determine the reliability of their estimates.
A number of definitions and methods of determining identifiability exist in the
literature. The method that has been utilized in this thesis is the one presented
by Raue et al. [31] in which they focus on distinguishing structural and practical
non-identifiable parameters from the ones being fully identifiable. This is done by
utilizing the profile likelihood (PL) to search for non-identifiabilities. The identi-
fiability analysis was performed using the virus data from upper respiratory tract
from Mallia et al.
The approach will be presented by first introducing the connection between weighted
least squares (WLS) and maximum likelihood (ML) followed by the connection
between maximum likelihood and profile likelihood. Lastly the fundamentals for
calculating confidence intervals by using the profile likelihood will be given.
Connection between weighted least squares, maximum likelihood and pro-
file likelihood
When a model is fitted to data the agreement of the fit to the experimental data is
often measured using an objective function, like the weighted least squares intro-
duced in the model section of this thesis and presented again below.
WSS =∑
i
(
xi− f (xi,θ)
σi
)2
(3.19)
With the weighted least square method the objective function, WSS, is minimized
in order to find the set of parameters θ that yield the best fit to the data, xi. In
equation 3.19 the vector of observations can also be written xi = yi + εi where
yi are the true measurement values and εi are the noise that is added to each
measurement. In this project the data from Mallia et al. was assumed to have
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normally distributed observational noise with zero mean and known variance, i.e
εi ∼N (0, σ2i ) .
The maximum likelihood can also be used for parameter estimation and the method
are in those cases referred to as maximum likelihood estimation (MLE). The like-
lihood, L(θ |x1..xN), gives the likelihood of observing a desired set of parameters
θ given a certain set of data, x1..xN . The higher the likelihood becomes the higher
are the chances to obtain the desired parameters and therefore the likelihood func-
tion is maximized.
As previously stated the observational noise in the measurements from Mallia et
al. were assumed to have a gaussian distribution. This implies that the probability
of observing a single data point xi is given by the probability density function
(PDF), equation 3.20, of the Gaussian distribution. The PDF should not be con-
fused with the output of the DDEs and is therefore denoted with the subscript
PDF.
f (xi,θ)PDF =
1√
2piσ2i
exp
(
−(xi−µi)
2
2σ2i
)
(3.20)
In equation 3.20 the PDF of a single data point xi is given and σi and µi denotes
the standard deviation and mean. Since the data set utilized in this thesis does not
consist of only one sample but a vector of samples the joint PDF of these samples
was required. If the data is discrete the joint PDF of a vector of independent
observations is equal to the product of the PDFs for each sample, equation 3.21.
f (x1...xN ,θ)PDF = f (x1,θ)PDF ... f (xN ,θ)PDF =
N
∏
i=1
f (xi,θ)PDF (3.21)
The likelihood function is by definition the joint PDF of the observations and can
hence be written as in equation 3.22
L(θ |x1...xN) =
N
∏
i=1
f (xi,θ)PDF =
N
∏
i=1
1√
(2piσ2i )n
exp
(
−(xi−µi)
2
2σ2i
)
(3.22)
To recall from previously the goal in MLE is to maximize the likelihood in order
to find the optimal parameters. This is achieved by taking the derivative ∂L∂θ of
equation 3.22, set it equal to zero and solve for θ . In this process equation 3.22 is
often logaritmized on both sides in order to make the computations easier. Since
the logarithm is an increasing function maximizing it will be equal to maximizing
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the non logaritmized function. It yields:
log(L(θ |x1...xN)) =−12
N
∑
i=1
(xi−µi)2
σ2
log
(
1√
(2piσ2i )n
)
(3.23)
The term log( 1√
(2piσ2i )n
) does not effect the estimate on θ and can therefore be
removed when taking the derivative of equation 3.23. Furthermore suppose that
the mean, µ , is given as a function of x that is depending on θ . This makes it
equivalent to the output from the DDEs. The final result after taking the logaritm
and derivative can be seen in equation 3.24.
∂
∂θ
(
log(L(θ |x1...xN))
)
=−1
2
N
∑
i=1
(xi− f (xi,θ))2
σ2i
(3.24)
The next step in the process of finding the optimal parameters would be to set
equation 3.24 to zero and solve for θ . Although this will not be done here since the
purpose of the above calculations were to show the connection between weighted
least squares and maximum likelihood. Finally the connection between the log
likelihood and weighted least squares optimizer can be summarized as
WSS = constant−2log(L(θ |x1...xN)) (3.25)
which imply that for normally distributed observational noise minimizing the
weighted least square is equal to maximizing the log likelihood. [31]
Profile likelihood
The likelihood can also be used if the aim is to estimate only one of the total num-
ber of parameters and it is then called the profile likelihood. This can be done if
the parameters that are not of interest, the nuisance parameters, can be expressed
as a function of the desired parameter. Then the likelihood becomes a function of
the single parameter, θi, when maximized over all the other parameters θ j 6=i. [32]
PL(θi) = max
θ j 6=i
(log L(θ j)) (3.26)
Profile likelihood confidence intervals
By exploring the profile likelihood, Raue et al. postulate that it is possible to de-
tect structural and practical non-identifiabilities. This is achieved by determining
likelihood based confidence intervals. In [31] the following definition of a CI is
given:
A confidence interval [σ−i ,σ
+
i ] of a parameter estimate θi to a con-
fidence level α signifies that the true value θ ∗i is located within this
interval with probability α .
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This implies that even though an estimate has successfully been found for a pa-
rameter its true value can only be guaranteed to lay within the confidence interval
with a certain probability for which the uncertainties are described by the confi-
dence intervals.
Likelihood ratio test
The idea of the PL based confidence intervals is to invert a likelihood ratio test to
obtain CIs for the desired parameter. In the likelihood ratio test a null hypothesis
and an alternative hypothesis is defined, equation 3.27. The null hypothesis, H0, is
that the parameter of interest, θ , equals a fixed constant value θ0. The alternative,
two-sided hypothesis H1 is that θ is not equal to this value.
H0 : θ = θ0
H1 : θ 6= θ0
(3.27)
The definition of the test ratio is given by
2
(
logL(θ)− logPL(θ0)
)
≤ χ2(α,df) (3.28)
where the term logL(θ) is the output of the likelihood with the full parameter set
and the term logPL(θ0) is the output of the likelihood with a reduced number of
parameters i.e the profile likelihood. The term χ2(α,df) on the right hand side in
equation 3.28 denotes the 100(1-α)th percentile of the χ2 distribution with a de-
gree of freedom df. The χ2 distribution is used since the left side of equation 3.28
approximates to the χ2 distribution for large sample sets. If θ0 fulfills equation
3.28 then the null hypothesis would not be rejected. Hence, a 100(1−α) con-
fidence interval for a parameter consists of all possible values of theta for which
the null hypothesis would not be rejected at a significance level α .
In the identifiability analysis performed in this thesis 95% confidence intervals
were desired. The degree of freedom, df, is often chosen to be 1 which yields
confidence intervals that are individual for each parameter. From the table with
the χ2 distribution this gives χ2α=0.95,df=1=3.84. Then a 95%-confidence interval
for a parameter contains those values of θ for which the left hand side of equation
3.28 does not exceed 3.84. Graphically this can be viewed in figure 3.2. Here the
result from the full model is demonstrated by the round black dot and the 95%
interval includes all values of θ for which the loglikelihood function drops off by
no more than 1.92.
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Figure 3.2: A profile likelihood calculated using the likelihood function. The
black dot represents the likelihood estimated with the full parameter set. The
threshold for the 95% CI is marked by the dashed red line.
As previously shown, for gaussian observational noise the maximum likelihood
and profile likelihood is connected as in equation 3.25. By using this relation and
substituting the logarithmized likelihood terms in equation 3.28 the test ratio can
be written as in equation 3.29 below.
2
(
const.−WSS(θ)
2
− const.−WSS(θ0)
2
)
≤ χ2(α,df) = 3.84 (3.29)
After cancelling the constants and re-arranging the terms this equation becomes
WSS(θ0)−WSS(θ)≤ 3.84 (3.30)
This relation can be viewed graphically in figure 3.3. Here the result from the full
model is denoted by the black asterisk and a 95% interval includes all values of
θ for which the error of the weighted least square optimizer does not increase by
more than 3.84.
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Figure 3.3: A profile likelihood calculated using weighted least squares. The as-
terisk denote the error from the WLS optimizer calculated with the full parameter
set. The threshold for the 95% CI is marked by the dashed red line.
By showing the above relation Raue et al. were able to use the weighted least
square to calculate profile likelihoods and determine confidence intervals for a
given parameter.
Structural and practical non-identifiabilities
The profile likelihood shown in figure 3.3 exceeds the 95% confidence level on
both sides of the estimate achieved with the full model. However this is not always
the case and by determining the CIs using the profile likelihoods it is possible to
obtain non-identifiabilities.
Graphically a profile likelihood that is completely flat in both directions indi-
cate on a structural non-identifiability. A structurally non-identifiable parameter
occurs as a result of a redundant parameterization of the model. Varying such a
parameter will not change the trajectories of the variables in the model and will
hence keep the WSS on a constant level, the CIs are infinite [−∞,∞]. A parameter
is structurally identifiable only if a unique minimum in the PL exists. An example
of the PL for a structurally non-identifiable parameter can be seen in figure 3.4,
left panel. In the three plots in figure 3.4 the red line represents χ2α=0.95,df=1=3.84.
The values of the x-axis where the PL crosses the red line represent the lower and
upper boundary of the confidence intervals.
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Figure 3.4: Three different outcomes of the profile likelihood. Parameter θi is
varied in both directions of the value obtained by the full model, indicated by
the black asterisk, and the other parameters are re-optimized for each step. The
dashed red line marks the threshold χ2α=0.95,df=1. The CIs are marked by [σ
−,σ+].
Left panel: structural non-identifiability, mid panel: practical non-identifiability,
right panel: fully identifiable.[33]
A parameter that is structurally identifiable may still be practically non-identifiable.
A practically non-identifiable parameter can be recognized with a PL that has a
minimum and exceeds the χ2α=0.95,df=1 threshold in either increasing or decreas-
ing directions but not in both. This means that one of the CIs is finite while the
other is still infinite. The cause is often an insufficient amount of data or data
with a low signal to noise ratio. A modification of a practically non-identifiable
parameter results in a small change of the trajectory it governs. However it may
have a bigger effect on the trajectories of the other species. An example of prac-
tical non-identifiability can be seen in the mid panel of figure 3.4.
If the parameter is fully identifiable it has finite CIs and a PL that exceeds the
threshold in both directions from the result obtained with the full model. The PL
of an identifiable parameter can be seen in the right panel of figure 3.4.
3.4.1 Resolving non-identifiabilities
Estimates from non-identifiable parameters might be spurious and unreliable.
However, the results from the identifiability analysis can be used to either plan
new experiments or to reduce the model which possibly could resolve some of
the non-identifiabilities.
Structural non-identifiability can only be resolved by modifying the design of
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the model and not by adding more data. Such a modification of the model could
for example be to add more species, provide the model with initial conditions or
fix a parameter to a user-defined value that yields the desired outcome. Practical
non-identifiablity can in some cases be resolved by adding more data. In such
cases the data should preferably be of the species the parameter is governing.
Furthermore the parameter can be set to zero. i.e by removing the corresponding
reaction from the model. [25]
In this part of the identifiability analysis the data set of IL-8 and IL-6 from Mallia
et al. was added so that the DDE model was fitted to virus, IL-8 and IL-6 data
simultaneously.
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Chapter 4
Results
4.1 The model
The results from the fitting procedure can be seen in figure 4.1 and 4.2. In these
figures the data sets from Mallia et al. are presented with their respective error
bars. The trajectories that do not have error bars are the results from the DDE
model.
Susceptible and infected cells
The upper left panel of figure 4.1 shows the trajectories of the susceptible and
infected cell variables. The number of infected cells increase as they are infected
by free virus and peak between 4-5 days post infection (dpi.) followed by a de-
crease. The number of infected cells at day 42, the last day of measurement, is 11.
Virus
In the upper right panel the virus data collected in the upper respiratory tract is
shown with error bars and the fitted virus trajectory can be seen in red.
IFN-β
The first response and threat to the virus infection is the increased production of
IFN-β , seen in the lower left panel of figure 4.1. These molecules inhibit the vi-
ral infection of susceptible cells and is hence responsible for the saturation of the
viral increase. The trajectory of IFN-β has the peak load 4-5 dpi.
IL-8
In the lower right panel of figure 4.1 the data of IL-8 from the lower respiratory
tract is presented in blue. The red trajectory represents the fit of IL-8 and it has a
peak load after 4-5 dpi.
Neutrophils
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Figure 4.1: Results of fitting the DDE model to the dataset of virus, IL-8, IL-6 and
neutrophils. Upper left panel: susceptible and infected cells, upper right panel:
virus and virus data from the upper respiratory tract, lower left panel: IFN-β ,
lower right panel: IL-8 and IL-8 data from the lower respiratory tract.
The neutrophils increase as a response to increased levels of IL-8. In the upper
left panel of figure 4.2 data from the lower respiratory tract of neutrophils is pre-
sented with error bars. The red trajectory is the fit of neutrophils. It has a peak at
9 dpi.
IL-6
In the upper right panel the fit of IL-6 can be seen in red and the data of IL-6 from
the lower respiratory tract is marked by the error bars. The peak concentration of
the fit occur 9 dpi.
IP-10
In the lower left panel of figure 4.2 the concentration of IP-10 can be seen. IP-10
is produced as a response to IFN-β production and it has a peak at 6 dpi.
CD8+ T-cells
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As a response to IL-6 and IP-10 the CD8+ T-cells migrate to the site of infection.
The trajectory of CD8+ T-cells can be seen in the lower right panel of figure 4.2.
The peak occurs between 9-11 dpi.
Figure 4.2: Results of fitting the DDE model to the dataset of virus, IL-8, IL-6
and neutrophils. Upper left panel: neutrophils and neutrophil data from the lower
respiratory tract, upper right panel: IL-6 and IL-6 data from the lower respiratory
tract, lower left panel: IP-10, lower right panel: CD8+ T-cells.
Estimates for the parameters in the DDE model can be seen in table 4.1. The
parameter estimates are given with the reference ranges that were found for some
of the parameters and used as parameter boundaries in the fitting procedure.
4.2 Sensitivity Analysis
4.2.1 Virus sensitivity
In the first part of the analysis the sensitivity of the model in terms of virus con-
centration was examined. The parameters were varied independently from 0.5,
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Parameter Estimate Units Param. ranges from literature Ref
β1 1.4624e-05 (copies/ml)−1(day)−1 [6e-06, 1.7e-04] [26]
β2 2.240 (day)−1 [2.5e-01, 4.0] [27]
β3 7.01 (copies/ml)(day)−1 - -
β4 1.2557e-04 dim.less [1e-08, 3.4e-03] [23]
β5 2.4951 (molecules/cell)(day)−1 - -
β6 17.0897 (day)−1 [1, 80] [27]
β7 1.0903e-05 (day)−1(cell)−1 - -
β8 0.12 (pg/ml)(cell)−1(day)−1 [3.8e-03, 1.5e-01] [28]
β9 12.02 (day)−1 [1, 80] [27]
β10 0.035 (Neutrophils/day)(pg/ml)−1 - -
β11 0.306 (day)−1 [1e-01, 2.4] [28]
β12 9.9090e-04 (Neutrophil)−1(day)−1 [2.5e-06, 1e-03] [28]
β13 7.9671e-06 (molecules/cell)(day)−1(pg/ml)−1 - -
β14 0.016 (pg/ml)(cell)−1(day)−1 [3.8e-03, 1.5e-01] [28]
β15 0.15 (day)−1 [3.8e-03, 1.5e-01] [28]
β16 1.2857 (cells/day)(ml/pg)−1 - -
β17 12.6389 (cells/day)(ml/pg)−1 - -
β18 8.6322e-05 (day)−1(cell)−1 [1e-06, 1e-05] [10]
β19 0.000003 (molecules)−1(day)−1 - -
δV 5 (day)−1 [3.1, 8.7] [26]
δT 0.1 (day)−1 [1e-02, 1e-01] [29]
gS 700 (day)−1 - -
gC 2.8788e+03 (pg/ml)(day)−1 - -
gN 20 (cells/day) - -
gL 250 (pg/ml)(day)−1 - -
τ1 50 (h) peak approx. 1-2 dpi. [1]
τ2 80 (h) peak approx. 9-12 dpi. [30]
τ3 30 (h) peak approx. 3 dpi. [23]
Table 4.1: The parameters in the DDE model. Estimated values can be seen with
thir respective units and parameter reference ranges, if available, from literature.
0.75, 1.5 and 2 times the initial best fit values according to the OFAT-approach.
The model was re-run for each change of parameters and the results were com-
pared between the new and old trajectory using the l2-norm. The output from the
norm was normalized with the peak value of the default trajectory to make the
results easier to compare. The l2-norms for each step and parameter are presented
in table 4.2. As a complement the trajectories of each parameter change were
plotted and the result can be seen in Appendix B.
Large values of the l2-norms indicate a significant change of the virus trajectory
meaning that the virus load is sensitive for changes of this parameter. The param-
eters β1 to β7 as well as δV all have large values indicating that they are sensitive
parameters. This is supported by the trajectories of these parameters seen in figure
B.1 and B.2.
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Parameter change
Parameter 0.5 0.75 1.5 2
β1, Infection rate of susceptible cells 2.3775 1.2281 1.6870 2.5521
β2, Decay rate of infected cells 1.1187 0.5411 0.9545 1.7661
β3, Virus production rate 2.2613 1.3013 2.6191 4.9249
β4, Inhibition of viral production by IFN 1.8954 0.7232 0.8298 1.2646
β5, Production of IFN by infected cells 1.9746 0.7427 0.8364 1.2695
β6, Decay rate of IFN 1.2654 0.6188 1.0793 1.9775
β7, Infection rate of susceptible cells 1.9170 0.9080 1.3303 2.0404
β8, Production rate of IL-8 0.0177 0.0088 0.0175 0.0348
β9, Decay rate of IL-8, IL-6 and IP-10 0.3410 0.1226 0.1374 0.2126
β10, Migration rate of neutrophils 0.0250 0.0124 0.0245 0.0485
β11, Decay rate of neutrophils 0.0564 0.0226 0.0276 0.0437
β12, Kill rate by neutrophils 0.0513 0.0255 0.0501 0.0992
β13, Production rate of IFN by DCs 0.0012 6.17e-04 0.0012 0.0025
β14, Production rate of IL-6 0.0098 0.0050 0.0096 0.0192
β15, Production rate of IP-10 0.1694 0.0817 0.1485 0.2851
β16, Migration rate of T-cells by IL-6 0.0132 0.0066 0.0130 0.0259
β17, Migration rate of T-cells by IP-10 0.1694 0.0817 0.1484 0.2851
β18, Kill rate by T-cells 0.1837 0.0882 0.1589 0.3034
β19, Apoptosis rate induced by IFN 0.0113 0.0056 0.0111 0.0221
δV , Virus decay rate 1.8551 0.6755 0.7912 1.2730
δT , T-cell decay rate 0.0585 0.0282 0.0494 0.0905
gS, Baseline growth of susceptible cells 0.0109 0.0055 0.0119 0.0266
gC, Baseline growth of IL-8 0.0087 0.0044 0.0087 0.0173
gN , Baseline growth of neutrophils 0.0226 0.0113 0.0225 0.0449
gL, Baseline growth of IL-6 0.049 0.0024 0.0047 0.0095
Table 4.2: Normalized l2-norm values between virus default trajectory and the
trajectories obtained with each modified parameter. Each parameter was modified
to 0.5, 0.75, 1.5 and 2 times the default value, the system was resolved and the
l2-norm was calculated between the default curve and the ones obtained with the
changed parameters. The output was then normalized with the peak concentration
of the default virus trajectory.
4.2.2 Sensitivity of the other variables
The extended sensitivity analysis was done by using the OFAT-approach while
observing the changes of the other variables as the parameters were modified. For
each parameter four l2-norm values were achieved per variable yielding in a table
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like the one presented below for β1. The result of the other parameters can be
seen in Appendix A.
Parameter β1. l2-norms
Parameter change IFN IL-8 Neutrophils IL-6 IP-10 T-cells
0.5 1.8857 1.4017 0.7988 1.5220 1.8578 2.6650
0.75 1.1918 0.8859 0.4003 0.9636 1.1755 1.1043
1.5 1.800 1.3375 0.4910 1.4800 1.8003 1.1894
2 2.9471 2.1865 0.7389 2.3066 2.8184 1.7607
Table 4.3: Normalized l2-norm values between the default trajectory of each vari-
able and the trajectories obtained when changing parameter β1. The l2-norms
were normalized with the default peak value of the respective variable.
Based on the l2-norm values the parameter was classified as stable, partly sta-
ble and sensitive for each variable. Stable were those parameters that had an
extremely small affect on the variables. Changing these parameters resulted in
l2-norm values in ranges of 1e-05 to 1e-01. Partly sensitive were parameters that
resulted in l2-norm values in the range of 1e-01 to 1 and sensitive were the pa-
rameters with l2-norm values above 1. The parameters and their classifications
for different variables can be seen in table 4.4.
Parameter IFN IL-8 Neutrophils IL-6 IP-10 T-cells Virus
β1 Sensitive Sensitive PartlySensitive Sensitive Sensitive Sensitive Sensitive
β2 Sensitive Sensitive Partly Sensitive Sensitive Sensitive Sensitive Sensitive
β3 Sensitive Sensitive Partly Sensitive Sensitive Sensitive Sensitive Sensitive
β4 Partly Sensitive Partly Sensitive Partly Sensitive Partly Sensitive Partly Sensitive Partly Sensitive Sensitive
β5 Partly Sensitive Partly Sensitive Partly Sensitive Partly Sensitive Partly Sensitive Sensitive Sensitive
β6 Partly Sensitive Partly Sensitive Partly Sensitive Partly Sensitive Partly Sensitive Sensitive Sensitive
β7 Sensitive Sensitive Partly Sensitive Sensitive Sensitive Sensitive Sensitive
β8 Stable Sensitive Partly Sensitive Stable Stable Stable Stable
β9 Stable Sensitive Sensitive Sensitive Sensitive Sensitive Partly Sensitive
β10 Stable Stable Sensitive Stable Stable Stable Stable
β11 Stable Stable Sensitive Stable Stable Stable Stable
β12 Stable Stable Stable Stable Stable Stable Stable
β13 Stable Stable Stable Stable Stable Stable Stable
β14 Stable Stable Stable Sensitive Stable Stable Stable
β15 Stable Stable Stable Stable Sensitive Sensitive Partly Sensitive
β16 Stable Stable Stable Stable Partly Sensitive Partly Sensitive Stable
β17 Stable Stable Stable Stable Stable Sensitive Partly Sensitive
β18 Stable Stable Stable Stable Stable Partly Sensitive Partly Sensitive
β19 Stable Stable Stable Stable Stable Stable Stable
δv Sensitive Partly Sensitive Partly Sensitive Partly Sensitive Sensitive Sensitive Sensitive
δT Stable Stable Stable Stable Stable Sensitive Stable
gS Stable Stable Stable Stable Stable Stable Stable
gC Stable Sensitive Sensitive Stable Stable Stable Stable
gN Stable Stable Sensitive Stable Stable Stable Stable
gL Stable Stable Stable Sensitive Stable Partly Sensitive Stable
Table 4.4: Parameter - Variable sensitivity chart.
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4.2.3 Use of the model to test two hypotheses
Elevated neutrophil levels
Mallia et al. showed in [1] that the number of neutrophils are higher in COPD
patients than in controls during an infection. In order to test if these results also
could be observed with the DDE model the parameters governing the baseline
level of IL-8 (gC), the baseline growth of neutrophils (gN) and the neutrophil mi-
gration rate (β10) were increased while changes of the neutrophil trajectory was
observed. Before varying the parameters the initial condition was increased to the
baseline level obtained in the COPD subjects.
Figure 4.3 shows the neutrophil trajectory when the parameters are changed one
at a time. The result is presented with the COPD data in black and control data in
blue. The red trajectory is the output of the DDE model.
(a) Baseline growth of IL-8 increased
with a factor 1.9
(b) Baseline growth of neutrophils in-
creased with a factor 1.9
(c) Neutrophil migration rate increased
with a factor 2.5
Figure 4.3: Result of increasing the parameters governing the baseline level of
IL-8 (gC), the baseline growth of neutrophils (gN) and the neutrophil migration
rate (β10). Control data is presented in blue and COPD data is presented in black.
The red trajectories represent the neutrophil quantity.
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Impaired production of IFN-β
Based on the results in [1] Mallia et al. also suggested that a deficient IFN-β pro-
duction may lead to increased susceptibility for COPD patients. The production
rate of IFN-β by infected cells (β5) and the production rate of IFN-β by den-
dritic cells (β13) were decreased to 1e-05 of their respective default values and
the changes in viral load was observed. When parameter β5 was decreased the
virus peak concentration increased to a peak of 5.4418 log10 copies/ml as seen
in figure 4.4. When parameter β13 was decreased no considerable change of the
virus trajectory could be observed.
Figure 4.4: Result of decreasing the IFN-β production rate by infected cells (β5)
to 1e-05 of its default value. Data from COPD patients can be seen in orange
with error bars, data from controls can be seen in blue with error bars and the red
trajectory is the output from the DDE model.
4.3 Identifiability Analysis
In the first part of the identifiability analysis the data of virus from the upper
respiratory tract was used for optimization. This resulted in 14 practically non-
identifiable parameters and one structurally non-identifiable parameter which can
be seen in table 4.5.
4.3.1 Resolving non-identifiabilities
After adding the data of IL-6 and IL-8 the identifiability analysis was performed
anew. This yielded in 8 practically non-identifiable parameters and one struc-
turally non-identifiable parameter of which can be seen in table 4.6.
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Parameter Non-identifiability
β1
β2
β3
β4
β5
β6
β7 Practical
β8 Practical
β9
β10 Practical
β11 Practical
β12 Practical
β13 Practical
β14 Practical
β15 Practical
β16 Practical
β17 Practical
β18
β19 Practical
δV
δT Structural
gS Practical
gC Practical
gN Practical
gL
Table 4.5: Result of the identifiability analysis obtained when using the virus data
for optimization. The parameters that are not marked with a non-identifiability
were fully identifiable.
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Parameter Non-identifiability
β1
β2
β3
β4
β5
β6
β7
β8
β9
β10 Practical
β11 Practical
β12 Practical
β13 Practical
β14
β15 Practical
β16 Practical
β17
β18
β19 Practical
δV
δT Structural
gS
gC
gN Practical
gL
Table 4.6: Result of the identifiability analysis performed using the data sets of
virus, IL-8 and IL-6.
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Chapter 5
Discussion
5.1 Model
The model was able to reproduce the data and the viral dynamics from the upper
respiratory tract as well as IL-8 and neutrophil dynamics from the lower respira-
tory tract. For IFN-β , IP-10 and CD8+ T-cells there were no data available for
fitting and reference values for some of the parameters could not be found in the
literature. As a result this made it more difficult to determine the reliability of
the the model dynamics of these variables. ODEs are valuable for studying vi-
ral dynamics in a well-mixed system, however the model presented in this thesis
included both variables that are expressed locally at the site of infection, like cy-
tokines, and variables that are not normally present in the tissue but migrate to
the site of infection, like neutrophils. The spatial effects are likely important and
a model that accounts for the location of different cells and molecules may better
represent the dynamics.
Susceptible cells
The susceptible cells were modeled with a constant growth term, gS. This was
done in order to avoid the model becoming target limited since this is an unlikely
situation in vivo where there will always be new epithelial cells for the virus to
infect. According to Christopher McCrae, results from AstraZeneca have showed
that infected cells returned to susceptible again during an HRV infection. This
could be added to the model by a new state variable that accounts for the recov-
ered cells. Another option could be to connect the infected and susceptible cells
by adding two terms that account for the recovery. However this would result in
more parameters to estimate.
Infected cells
The infected cells were initialized to zero and after the peak the quantity declined
to 10 cells. For the parameters with reference boundaries from literature only the
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killing rate of infected cells by CD8+ T-cells (β18) got an estimate outside the
reference range. However the reference, from [10], was an estimate made from
killing rate by NK-cells and not a result of CD8+ T-cells from clinical experimen-
tation.
Virus
The model was able to capture the dynamics of virus concentration. Between
baseline and day 1 a rapid decrease appeared in the viral trajectory. This was be-
cause the model was initialized with 10 copies/ml of free virus and zero infected
cells. Until a cell has been infected no viral production occurs and as a result
the concentration decreased during the first day due to removal of free virions by
mucus and normal decay. In the model the virus production was assumed to start
as soon as target cells became infected but virus may also be released when in-
fected cells lyse [10]. The proportion of virions released through cell lysis is not
known which complicates the process of creating a model that accounts for both.
Furthermore virus was modeled with a term representing the virions that infect
the susceptible cells, β7SV . These virions were removed from the pool of free
virus in the mucus and hence modeled as a decrease. Modeling the virus with a
term like this has previously been done in [10] and [22].
IFN-β
From Mallia et al. there was no data available for IFN-β which made it difficult
to validate the final result. IFN are known to be one of the first mediators of
the innate immunological defence and they are usually present 1-2 days after the
virus peak [3]. Based on these results the model seems to capture the peak time of
IFN-β since it appears 4-5 dpi. which is approximately 1-2 days after the start of
the virus peak. In this model IFN-β inhibit the viral replication through the term
β3
1+β4F where β3 is the virus production rate and β4 is the effectiveness of IFN-β .
This way of modeling the interference between IFN-β and virus has previously
been used in [26]. For simplicity the DCs were modeled as a constant instead of
a variable in this model.
IL-8
The model is able to capture the dynamics of IL-8 from the lower respiratory
tract. The decay rate, β9, was chosen to be the same for all cytokines in the model
(IL-8, IL-6, IP-10 and IFN) in order to keep the number of parameters as low as
possible. The parameter range that was used as reference for fitting was large and
the final estimate seemed to give a good fit for IL-8.
Neutrophils
The model was able to capture the neutrophil data from the lower respiratory tract
well. In the data from the lower respiratory tract the baseline level was non zero
40
and the quantity decreases to the same levels after the peak has occurred. These
results suggest that a baseline migration that is not dependent on the infection is
needed in order to replicate the clinical results. The delay used on the migration
rate of neutrophils from IL-8 was necessary to get the peak to accord with data.
IL-6
The results show that the model was not sufficient to describe the dynamics
of IL-6 from the lower respiratory tract. After discussion with Hoda Sharifian
at AstraZeneca the conclusion was made that one reason for this may be that
macrophages, which function as important producers of IL-6, were excluded from
the model. The delay of 80 hours, added to the production of IL-6 by infected
cells, was necessary to get the peak at 9-10 dpi. By adding the macrophages as
a variable the delay could possibly have been removed resulting in a slower in-
crease of IL-6.
IP-10
For IP-10 there were no data available from the study by Mallia et al. In [22]
Mitchel et al. report that human bronchial epithelial cells, after being infected
with three types of influenza virus strains in vitro, expressed IP-10 already after
8 hours post infection and according to their data peaked 2-3 dpi. The model
developed in this thesis indicated that IP-10 increase started 3 dpi. and peaked
6 dpi. which is clearly delayed compared to the data presented by Mitchel et al.
Indeed a delay of 30 hours was added to the IP-10 equation but this was necessary
in order to delay the response of CD8+ T-cells. However, the peak concentration
and time may be larger and earlier in vitro than in vivo since in vitro experiments
do not include other biological mechanisms that is part of the immune response
in the human body. Furthermore Mitchel et al. only collected data for the first 72
hours.
CD8+ T-cells
For CD8+ T-cells there were no data available from the study by Mallia et al. The
T-cells are part of the adaptive immune response and arrive to the cite of infection
after they have been activated by dendritic cells. Hence they are not observed
until 1-2 weeks after the infection starts [14]. The CD8+ T-cell trajectory showed
a peak at 9-11 dpi which could be a valid estimation according to literature. The
migration of CD8+ T-cells was induced by IL-6 and IP-10 in the model but ref-
erence boundaries of which of them that accounts for the major production could
not be found.
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5.2 Sensitivity Analysis
A sensitivity analysis was performed on 25 of the parameters in the DDE model.
The parameters that were excluded were the time constants τ1,τ2,τ3 in the delay
equations. These delays were part of the equations governing the peaks of IL-6,
neutrophils and IL-8. Small changes of the peak time for these variables appeared
to only notably effect the dynamics of the other variables and therefore they were
excluded from the sensitivity analysis.
5.2.1 Virus sensitivity
Results from the first part of the sensitivity analysis, when only the sensitivity
of virus was observed as the parameters were varied, showed that the virus was
sensitive for parameter β1 to β7 as well as δV . This was expected since these
parameters are connected to either the production or decrease of infected cells,
IFN-β or the virus itself. Based on the trajectories plotted as each of the param-
eters were varied, shown in figure A.1, the virus was most sensitive in the end of
the infection period. Parameter β1 to β7 and δV seemed to have the biggest effect
on the virus. The peak seemed to be mostly sensitive for changes of β2, β7 and δV
whereas the time of the peak was most sensitive for changes of β1, β3 and β7. To
achieve more accurate results a more detailed sensitivity analysis with individual
boundaries for each parameters should preferably be performed. For some param-
eters a variation from 0.5 to 2 times the initial estimate is not enough to be able to
make conclusions whether it has an impact on viral load or not. Larger variations
were tested throughout the analysis but for some parameters the system became
unstable and since it was desirable to use the same ranges for all parameters in
order to maintain the structure through the analysis the the safer ranges between
0.5 an 2 were used.
5.2.2 Sensitivity of the other variables
In the second part of the analysis the sensitivity of all variables except infected
and susceptible cells were observed as the parameters were varied. The result was
used to construct a parameter - variable sensitivity chart. In this table it is possible
to read that all the variables, except neutrophils, are sensitive for changes in the
infection rate (β1) and turn over rate of infected cells (β2) since the production of
these variables is directly dependent on the number of infected cells. Neutrophils
are not directly connected to infected cells but depend on the production of IL-8
which makes the variable partly sensitive for β1 and β2. Moreover all variables
42
are either partly sensitive or sensitive to the production and decay rates of virus
and IFN-β , parameter β3 to β7 and δV .
Surprisingly the virus is stable for changing the killing rate of infected cells by
neutrophils (β12) and partly sensitive for changes of the killing rate by CD8+ T-
cells (β18). This suggests that most of the infection is cleared by T-cells rather
than neutrophils. Furthermore the CD8+ T-cells are more sensitive to changes
of the migration rate by IP-10 than of IL-6. This implies that it might be more
important to compliment this study with data for IP-10, if available, rather than to
search for data for IL-6 from the upper respiratory tract.
5.2.3 Use of the model to test two hypotheses
Elevated neutrophil levels
In this hypothesis the three parameters baseline growth of neutrophils (gN), base-
line growth of IL-8 (gC) and neutrophil migration rate (β10) were increased while
changes in the neutrophil trajectory were observed. Compared to changes of the
neutrophil migration rate(figure 4.3b), increasing the baseline growth of IL-8 (fig-
ure 4.3a) and the neutrophilic growth rate (figure 4.3c) resulted in neutrophil dy-
namics that more closely captured COPD data. These results suggest that in-
creased neutrophil levels in COPD patients is due to increased baseline levels
rather than an increased migration rate.
Deficient production of IFN-β
When this hypothesis was tested the parameters governing IFN-β production by
infected cells (β5) and dendritic cells (β13) were decreased and changes of the
viral load was observed. As can be seen in figure 4.4, an impaired IFN-β pro-
duction by infected cells does not result in increased virus levels comparable to
COPD. However there are controversial results regarding the deficiency of IFN-
β production since experiments have been performed on different cell types and
different cell types express IFN-β differently.
As the parameter governing the production by dendritic cells was varied no changes
were observed in viral concentration. Results from the sensitivity analysis, pre-
sented in the sensitivity chart 4.4, also indicated that virus was not effected at all
by changes of β13 but the results indicating on the stability of this parameter were
more prominent here as it was decreased to 1e-05 of its original value. According
to these results the production by dendritic cells is negligible which is unlikely
since it is known that dendritic cells act as an important producer of IFN-β , ac-
cording to Christopher McCrae at AstraZeneca. Therefore a suggestion is to add
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the dendritic cells as a variable to be able to study its dynamics.
5.3 Identifiability Analysis
The identifiability analysis gave 14 practically non-identifiable parameters. These
parameters were all either classified as stable or partly sensitive in the sensitiv-
ity analysis on virus except for the infection rate of susceptible cells (β7) that
was classified as sensitive. For these practically non-identifiable parameters the
data contains information about the parameter but not enough to make them iden-
tifiable. CD8+ T-cell decay rate was the only parameter obtained structurally
non-identifiable. This parameter was classified as stable in the sensitivity analy-
sis and together with the results from the identifiability analysis this implies that
the model is not sufficient to describe its dynamics.
5.3.1 Resolving non-identifiabilities
After the data sets of IL-8 and IL-6 was added, 6 of the practically non-identifiable
parameters could be resolved. The ones that remained non-identifiable were pa-
rameters connected to variables for which there were no data utilized, as for ex-
ample β15 governing the production of IP-10 and β16 governing production of
CD8+ T-cells.
Parameter δT remained structurally non-identifiable since it is not possible to re-
solve a structurally non-identifiable parameter by adding more data. Since this
parameter was also marked as stable in the sensitivity analysis it could probably
be removed from the equation without effecting the overall dynamics of either
virus nor CD8+ T-cells.
5.4 Future Perspective
The next step in this project would have been to use the results from the identifi-
ability analysis to reduce the model by removing reactions that would not effect
the viral dynamics and that cannot be uniquely estimated with the available data.
Furthermore dendritic cells and macrophages would have been added as variables
to the model in order to better be able to describe IL-6 dynamics and the dynamics
of IFN-β governed by dendritic cells. It would also be of interest to fit the DDE
model to COPD data and observe how and which parameters that changed.
A second step would be to redo the sensitivity analysis with individual ranges
for each parameter. By exploring the extremes of each parameter it would be pos-
sible to make more accurate conclusions about their respective sensitivity. If so
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then the results presented in the sensitivity chart could possibly be used directly
to give answer to hypotheses made about the dynamics.
The long term goal would be to connect the DDE model with a spatial model.
Such a spatial model has in parallel with this project been developed by another
master thesis student at the Center of Systems Biology in Dresden. If this could
be done successfully then the spatiotemporal model could be used to run simula-
tions of how the infection front propagates from the upper to the lower respiratory
tract while being battled by the immune system. With such a model it could be
possible to investigate if the concentrations of inflammatory cells and cytokines
differ between the upper and lower respiratory tracts and between controls and
COPD patients. It could also be possible to investigate the importance of mucus
movement for accumulation of inflammatory cells and cytokines and the effects
this would have on the viral spread.
5.5 Ethical reflection
The data that was utilized in this thesis came from an experiment during which
COPD patients were infected with HRV. After inoculation the symptoms of the
subjects worsened to such a degree that all patients fulfilled the criteria for a
COPD exacerbation. Because the exacerbations were triggered as a result of the
infection, samples could be collected both before, during and after the exacerba-
tion period. The results from this type of controlled study were valuable in the
sense of studying the pathogenesis of HRV compared to studies performed on pa-
tients having naturally occuring exacerbations.
However, since the exacerbations can be life-threatening for the patients ethi-
cal approval from both authorities and the participants were required. The health
risks were high and since the patients could only be given symptom relieving
medication these types of studies are controversial.
One of the difficulties with developing all kind of pharmaca is that tests even-
tually have to be performed on humans. To a certain extent the computational,
in situ, models can be used as a complement or alternative to the experimental
models. If the model developed in this thesis successfully could be integrated in
a spatial model the dynamics of virus and inflammatory cells could be simulated
and tests that would otherwise have been performed during clinical experimenta-
tion could instead be tested on the model.
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Chapter 6
Conclusion
In this thesis a temporal model of the immune system during a virus infection
was developed. It includes immunological mechanisms that are believed to occur
during a COPD exacerbation triggered by a respiratory infection of Human Rhi-
novirus. The model was used to derive numerical values of kinetics in the immune
response and of the infection dynamics. By a sensitivity analysis it was outlined
which parameters of the model that may be of importance for the immune system
to clear the viral infection. An identifiability analysis showed that the model and
the available data were sufficient to describe the dynamics. If connected to a spa-
tial model, the model can in the future be used to simulate the viral and immune
dynamics in the human lung.
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Chapter 7
Variable & parameter definitions
Symbol Definition
S Susceptible epithelial cells
I Infected epithelial cells
V Free virions
F Free IFN-β
C Free IL-8
N Neutrophils
L Free IL-6
P Free IP-10
T CD8+ T-cells
DC Dendritic cells in the epithelial tissue
Table 7.1: Variable definitions.
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Parameter Definition
β1 Infection rate of susceptible cells
β2 Decay rate of infected cells
β3 Virus production rate
β4 Inhibition of viral production by IFN
β5 Production of IFN by infected cells
β6 Decay rate of IFN
β7 Infection rate of susceptible cells
β8 Production rate of IL-8
β9 Decay rate of IL-8
β10 Migration rate of neutrophils
β11 Decay rate of neutrophils
β12 Kill rate by neutrophils
β13 Production rate of IFN by DC
β14 Production rate of IL-6
β15 Production rate of IP-10
β16 Migration rate of T-cells by IL-6
β17 Migration rate of T-cells by IP-10
β18 Kill rate by T-cells
β19 Apoptosis rate induced by IFN
δV Virus decay rate
δT T-cell decay rate
gS Baseline growth of susceptible cells
gC Baseline growth of IL-8
gN Baseline growth of neutrophils
gL Baseline growth of IL-6
Table 7.2: Parameter definitions.
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Appendix A
Graphical results from sensitivity
analysis performed on virus
Here the trajectories from the sensitivity analysis performed on virus is shown.
The parameters that are presented are β1 to gL. In the figures the virus trajectory
obtained with the default parameter value can be seen in dark blue whilst the
trajectories obtained with the modified parameters have lighter colours.
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Figure A.1: Virus load during sensitivity analysis.
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Appendix B
Complete collection of l2-norms
from extended sensitivity
analysis
Here the normalized l2-norms from the extended sensitivity analysis is presented.
Each table belongs to a specific parameter. On the left the parameter variations
0.5 to 2 is shown and in the following columns the normalized l2-norm outputs
from the variations for each variable can be seen.
Parameter β1. L2 norms
Parameter change IFN IL-8 Neutrophils IL-6 IP-10 T-cells
0.5 1.8857 1.4017 0.7988 1.5220 1.8578 2.6650
0.75 1.1918 0.8859 0.4003 0.9636 1.1755 1.1043
1.5 1.800 1.3375 0.4910 1.4800 1.8003 1.1894
2 2.9471 2.1865 0.7389 2.3066 2.8184 1.7607
Parameter β2. L2 norms
Parameter change IFN IL-8 Neutrophils IL-6 IP-10 T-cells
0.5 1.8889 1.4041 0.7095 1.5147 1.8497 2.4686
0.75 0.7596 0.5642 0.2861 0.6076 0.7416 0.9931
1.5 0.9898 0.7358 0.3766 0.8015 0.9774 1.2934
2 1.5947 1.1854 0.6314 1.2880 1.5715 2.1845
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Parameter β3. L2 norms
Parameter change IFN IL-8 Neutrophils IL-6 IP-10 T-cells
0.5 1.8663 1.3874 0.7821 1.5066 1.8388 2.5887
0.75 1.1359 0.8443 0.3825 0.9186 1.1203 1.0587
1.5 1.7382 1.2926 0.4746 1.4365 1.7492 1.1521
2 2.8737 2.1277 0.7197 2.2386 2.7335 1.7161
Parameter β4. L2 norms
Parameter change IFN IL-8 Neutrophils IL-6 IP-10 T-cells
0.5 0.9211 0.6839 0.2532 0.7398 0.9037 0.6207
0.75 0.3762 0.2795 0.1130 0.3033 0.3704 0.2846
1.5 0.4795 0.3564 0.1673 0.3868 0.4722 0.4602
2 0.7667 0.5698 0.2817 0.6188 0.7552 0.8089
Parameter β5. L2 norms
Parameter change IFN IL-8 Neutrophils IL-6 IP-10 T-cells
0.5 0.7162 0.7017 0.2691 0.7590 0.7042 1.2168
0.75 0.3256 0.2847 0.1190 0.3088 0.3200 0.5833
1.5 0.5219 0.3589 0.1734 0.3897 0.5134 1.0787
2 0.9317 0.5719 0.2900 0.6211 0.9165 2.0438
Parameter β6. L2 norms
Parameter change IFN IL-8 Neutrophils IL-6 IP-10 T-cells
0.5 0.9288 0.5610 0.2850 0.6087 0.9141 2.0467
0.75 0.3621 0.2557 0.1212 0.2774 0.3562 0.7324
1.5 0.4477 0.3963 0.1624 0.4297 0.4403 0.7886
2 0.7179 0.6864 0.2648 0.7426 0.7062 1.2194
Parameter β7. L2 norms
Parameter change IFN IL-8 Neutrophils IL-6 IP-10 T-cells
0.5 1.5168 1.1290 0.4053 1.2443 1.5172 0.9726
0.75 0.7454 0.5532 0.2058 0.5853 0.7157 0.5050
1.5 1.1437 0.8500 0.3852 0.9248 1.1278 1.0492
2 1.7538 1.3037 0.6719 1.4164 1.7281 2.0138
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Parameter β8. L2 norms
Parameter change IFN IL-8 Neutrophils IL-6 IP-10 T-cells
0.5 0.00093 0.6761 0.3972 0.0075 0.0092 0.0141
0.75 0.0047 0.3376 0.1982 0.0038 0.0046 0.0070
1.5 0.0091 0.6726 0.3942 0.0074 0.0090 0.0139
2 0.0182 1.3418 0.7854 0.0148 0.0180 0.0275
Parameter β9. L2 norms
Parameter change IFN IL-8 Neutrophils IL-6 IP-10 T-cells
0.5 0.1835 2.3849 1.6093 2.0473 1.5665 2.6867
0.75 0.0676 0.8052 0.5451 0.6961 0.5419 0.9425
1.5 0.0766 0.8221 0.5576 0.7158 0.5661 1.0040
2 0.1188 1.2407 0.8421 1.0824 0.8605 1.5332
Parameter β10. L2 norms
Parameter change IFN IL-8 Neutrophils IL-6 IP-10 T-cells
0.5 0.0163 0.0121 0.8719 0.0131 0.0160 0.0285
0.75 0.0081 0.0060 0.4352 0.0065 0.0080 0.0142
1.5 0.0159 0.0118 0.8662 0.0128 0.0156 0.0279
2 0.0315 0.0235 1.7270 0.0255 0.0311 0.0553
Parameter β11. L2 norms
Parameter change IFN IL-8 Neutrophils IL-6 IP-10 T-cells
0.5 0.0506 0.0376 4.2193 0.0409 0.0498 0.0864
0.75 0.0216 0.0160 1.4739 0.0174 0.0213 0.0358
1.5 0.0292 0.0217 1.5391 0.0236 0.0288 0.0459
2 0.0473 0.0352 2.3322 0.0383 0.0466 0.0731
Parameter β12. L2 norms
Parameter change IFN IL-8 Neutrophils IL-6 IP-10 T-cells
0.5 0.0559 0.0415 0.0226 0.0450 0.0549 0.0818
0.75 0.0277 0.0206 0.0112 0.0224 0.0272 0.0405
1.5 0.0543 0.0404 0.0218 0.0437 0.0527 0.0788
2 0.1070 0.0795 0.0429 0.0862 0.1048 0.1548
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Parameter β13. L2 norms
Parameter change IFN IL-8 Neutrophils IL-6 IP-10 T-cells
0.5 7.9e-04 3.9e-04 1.9e-04 4.3e-04 7.7e-04 0.0015
0.75 3.9e-04 1.7e-04 9.6e-05 2.1e-04 3.9e-04 7.4e-04
1.5 7.8e-04 3.9e-04 1.9e-04 4.2e-04 7.7e-04 0.0015
2 0.0016 7.8e-04 3.8e-04 8.5e-04 0.0015 0.0029
Parameter β14. L2 norms
Parameter change IFN IL-8 Neutrophils IL-6 IP-10 T-cells
0.5 0.0038 0.0027 0.0016 0.7359 0.0036 0.1007
0.75 0.0020 0.0014 8.2e-04 0.3678 0.0019 0.0503
1.5 0.0034 0.0026 0.0016 0.7351 0.0035 0.1004
2 0.0071 0.0053 0.0032 1.4702 0.0069 0.2005
Parameter β15. L2 norms
Parameter change IFN IL-8 Neutrophils IL-6 IP-10 T-cells
0.5 0.0962 0.0715 0.0419 0.0776 0.8702 1.3563
0.75 0.0464 0.0345 0.0202 0.0375 0.4288 0.6632
1.5 0.0843 0.0627 0.0365 0.0680 0.8247 1.2487
2 0.1599 0.1189 0.0690 0.1288 1.6124 2.4112
Parameter β16. L2 norms
Parameter change IFN IL-8 Neutrophils IL-6 IP-10 T-cells
0.5 0.0065 0.0048 0.0032 0.0053 0.0064 0.2074
0.75 0.0033 0.0024 0.0016 0.0026 0.0032 0.1036
1.5 0.0065 0.0048 0.0032 0.0052 0.0064 0.2067
2 0.0129 0.0096 0.0063 0.0104 0.0127 0.4127
Parameter β17. L2 norms
Parameter change IFN IL-8 Neutrophils IL-6 IP-10 T-cells
0.5 0.0962 0.0715 0.0419 0.0776 0.0947 1.3563
0.75 0.0464 0.0345 0.0202 0.0375 0.0457 0.6632
1.5 0.0843 0.0627 0.0265 0.0680 0.0830 1.2487
2 0.1599 0.1189 0.0690 0.1288 0.1574 2.4112
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Parameter β18. L2 norms
Parameter change IFN IL-8 Neutrophils IL-6 IP-10 T-cells
0.5 0.1027 0.0763 0.0455 0.0829 0.1012 0.1725
0.75 0.0494 0.0367 0.0218 0.0399 0.0487 0.0827
1.5 0.0891 0.0662 0.0392 0.0718 0.0878 0.1477
2 0.1683 0.1251 0.0738 0.1355 0.1656 0.2762
Parameter β19. L2 norms
Parameter change IFN IL-8 Neutrophils IL-6 IP-10 T-cells
0.5 0.0137 0.0102 0.0048 0.0111 0.0135 0.0152
0.75 0.0068 0.0051 0.0024 0.0055 0.0067 0.0075
1.5 0.0134 0.0100 0.0047 0.0108 0.0132 0.0148
2 0.0265 0.0197 0.0093 0.0213 0.0260 0.0293
Parameter δV . L2 norms
Parameter change IFN IL-8 Neutrophils IL-6 IP-10 T-cells
0.5 0.7567 0.5617 0.2334 0.5972 0.7295 0.6295
0.75 0.3477 0.2578 0.1102 0.2748 0.3355 0.3035
1.5 0.5675 0.4217 0.1899 0.4626 0.5635 0.5465
2 1.0174 0.7562 0.3490 0.8232 1.0039 1.0278
Parameter δT . L2 norms
Parameter change IFN IL-8 Neutrophils IL-6 IP-10 T-cells
0.5 0.0212 0.0157 0.0105 0.0171 0.0208 1.9042
0.75 0.0102 0.0076 0.0051 0.0082 0.0101 0.7501
1.5 0.0184 0.0137 0.0090 0.0149 0.0182 0.8998
2 0.0344 0.0255 0.0168 0.0278 0.0339 1.4161
Parameter S. L2 norms
Parameter change IFN IL-8 Neutrophils IL-6 IP-10 T-cells
0.5 0.0053 0.0039 0.0028 0.0043 0.0052 0.0124
0.75 0.0027 0.0020 0.0014 0.0021 0.0026 0.0063
1.5 0.0055 0.0041 0.0028 0.0044 0.0054 0.0129
2 0.0114 0.0085 0.0058 0.0090 0.0111 0.0267
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Parameter C. L2 norms
Parameter change IFN IL-8 Neutrophils IL-6 IP-10 T-cells
0.5 0.0079 0.8240 0.5791 0.0063 0.0077 0.0127
0.75 0.0039 0.4120 0.2896 0.0032 0.0039 0.0063
1.5 0.0078 0.8240 0.5791 0.0063 0.0077 0.0126
2 0.0156 1.6481 1.1582 0.0126 0.0153 0.0252
Parameter N . L2 norms
Parameter change IFN IL-8 Neutrophils IL-6 IP-10 T-cells
0.5 0.0252 0.0188 1.4226 0.0204 0.0249 0.0383
0.75 0.0126 0.0094 0.7113 0.0102 0.0124 0.0191
1.5 0.0249 0.0185 1.4226 0.0201 0.0245 0.0378
2 0.0494 0.0367 2.8453 0.0399 0.0487 0.0751
Parameter L. L2 norms
Parameter change IFN IL-8 Neutrophils IL-6 IP-10 T-cells
0.5 0.0045 0.0033 0.0020 0.5824 0.0045 0.1238
0.75 0.0022 0.0017 9.8e-04 0.2913 0.0022 0.0619
1.5 0.0045 0.0033 0.0019 0.5826 0.0043 0.1238
2 0.0089 0.0066 0.0039 1.1651 0.0086 0.2477
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Appendix C
Likelihood Profiles from
identifiability analysis
Here the profile likelihoods for the identifiability analysis is presented. The anal-
ysis was performed on parameter β1 to gL. In the figures the asterisks mark the
parameter value that yielded the best fit and the red dashed line demonstrates the
95% confidence level.
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Parameter β1 Parameter β2 Parameter β3
Parameter β4 Parameter β5 Parameter β6
Parameter β7 Parameter β8 Parameter β9
Parameter β10 Parameter β11 Parameter β12
Parameter β13
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Parameter β14 Parameter β15 Parameter β16
Parameter β17 Parameter β18 Parameter β19
Parameter δV Parameter δT Parameter gS
Parameter gC Parameter gN Parameter gL
Figure C.1: Profile likelihoods from the identifiability analysis.
65
Appendix D
Likelihood Profiles from
extended identifiability analysis
Here the profile likelihoods for the extended identifiability analysis is presented.
The analysis was performed on parameter β1 to gL. In the figures the asterisks
mark the parameter value that yielded the best fit and the red dashed line demon-
strates the 95% confidence level.
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Parameter β4 Parameter β5 Parameter β6
Parameter β7 Parameter β8 Parameter β9
Parameter β10 Parameter β11 Parameter β12
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Parameter β14 Parameter β15 Parameter β16
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Parameter gC Parameter gN Parameter gL
Figure D.1: Profile likelihoods from the extended identifiability analysis.
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